Health effects of low level radiation: when will we acknowledge the reality?

The 1986 April 26th Chernobyl event was the worst nuclear power accident--it killed 31 people. Its significance was exaggerated immensely because of the pervasive fear of ionizing radiation that has been indoctrinated in all of humanity. In reality, our environment includes radiation from natural sources, varying widely in intensity, to which all living things have adapted. The effect of radiation on organisms is primarily on their damage control biosystem, which prevents, repairs and removes cell damage. Low doses stimulate this system, while high doses inhibit it. So low doses decrease the incidences of cancer and congenital malformations; high doses have the opposite effect. Efforts by radiation protection organizations to lower exposures to (human-made) radiation to as low as reasonably achievable (ALARA) provide no benefit. They only create inappropriate fear-barriers to very important applications of nuclear technology in energy production and medicine.

Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.

Immune Tolerance Therapy for Haemophilia A Patients with Acquired Factor VIII Alloantibodies: Comprehensive Analysis of Experience at a Single Institution Eleven children with severe haemophilia A associated with the IVS 22 inversion and acquired high titre neutralising antibodies to factor VIII underwent immune tolerance induction. HLA class I and high resolution class II type is detailed for each patient. A three phase approach to immune tolerance induction was used. During phase 1, which lasted a median of six weeks, patients received factor VIII 100 IU/kg twice daily. Phase 2 comprised a factor VIII dose reduction to 100 IU/kg once daily, and continued for a median duration of 14 weeks. Subsequently 10 of the 11 patients satisfied the criteria of absent factor VIII neutralising activity by the Bethesda method, and a factor VIII elimination half life of greater than 5 h, allowing progression to phase 3, a further factor VIII dose reduction to 50 IU/kg three times weekly. A model for dose reduction as factor VIII tolerance evolves, based on pharmacokinetic analysis, is described.